Claims for Patent: 6,548,657

Summary for Patent: 6,548,657

Title:	Method for screening nucleic acid catalysts
Abstract:	Nucleic acid catalysts, method of screening for variants of nucleic acid catalysts, synthesis of ribozyme libraries and discovery of gene sequences are described.
Inventor(s):	Burgin; Alex (Chula Vista, CA), Beigelman; Leonid (Longmont, CO), Bellon; Laurent (Boulder, CO)
Assignee:	Ribozyme Pharmaceuticals, Inc. (Boulder, CO)
Application Number:	09/216,584
Patent Claims:	1. An isolated and purified nucleic acid molecule with an endonuclease activity having formula I: ##STR2## wherein, N is independently a nucleotide or a non-nucleotide linker, which may be same or different; M and Q are independently oligonucleotides of sufficient length to stably interact with a target nucleic acid molecule; o and n are integers greater than or equal to 1, wherein if (N)o and (N)n are nucleotides, (N)o and (N)n are optionally able to interact by hydrogen bond interaction; L is a linker which may be present or absent, but when present, is a nucleotide and/or a non-nucleotide linker, which may be a single-stranded and/or a double-stranded region; represents a chemical linkage; and A, C, U and G represent adenosine, cytidine, uridine and guanosine nucleotides, respectively. 2. A nucleic acid molecule with catalytic activity having the formula II: ##STR3## wherein, N is independently a nucleotide or a non-nucleotide linker, which may be same or different; M and Q are independently oligonucleotides of length sufficient to stably interact with a target nucleic acid molecule; o and n are integers greater than or equal to 1, wherein if (N).sub.o and (N).sub.n are nucleotides, (N)o and (N)n are optionally able to interact by hydrogen bond interaction; L is a linker which may be present or absent, but when present, is a nucleotide and/or a non-nucleotide linker, which may be a single-stranded and/or double-stranded region; Z3 is 2'-methylthiomethyl uridine; Z4 is 2'-C-allyl uridine; Z7 is 6-methyl uridine; _ represents a chemical linkage; and A, and G represent adenosine and guanosine nucleotides, respectively. 3. A nucleic acid molecule with catalytic activity having the formula III: ##STR4## wherein, N is independently a nucleotide or a non-nucleotide linker, which may be same or different; M and Q are independently oligonucleotides of length sufficient to stably interact with a target nucleic acid molecule; o and n are integers greater than or equal to 1, wherein if (N).sub.o and (N).sub.n are nucleotides, (N)o and (N)n are optionally able to interact by hydrogen bond interaction; L is a linker which may be present or absent, but when present, is a nucleotide and/or a non-nucleotide linker, which may be a single-stranded and/or double-stranded region; Z3 is 2'-methylthiomethyl uridine; Z4 is 2'-methylthiomethyl cytidine; Z7 is 6-methyl uridine; represents a chemical linkage; and A, and G represent adenosine and guanosine nucleotides, respectively. 4. A nucleic acid molecule with catalytic activity having the formula IV: ##STR5## wherein, N is independently a nucleotide or a non-nucleotide linker, which may be same or different; M and Q are independently oligonucleotides of length sufficient to stably interact with a target nucleic acid molecule; o and n are integers greater than or equal to 1, wherein if (N).sub.o and (N).sub.n are nucleotides, (N)o and (N)n are optionally able to interact by hydrogen bond interaction; L is a linker which may be present or absent, but when present, is a nucleotide and/or a non-nucleotide linker, which may be a single-stranded and/or double-stranded region; Z3 is 2'-methylthiomethyl uridine; Z4 is 2'-methylthiomethyl cytidine; Z7 is 2'-C-allyl uridine; represents a chemical linkage; and A, and G represent adenosine and guanosine nucleotides, respectively. 5. A nucleic acid molecule with catalytic activity having the formula V: ##STR6## wherein, N is independently a nucleotide or a non-nucleotide linker, which may be same or different; M and Q are independently oligonucleotides of length sufficient to stably interact with a target nucleic acid molecule; o and n are integers greater than or equal to 1, wherein if (N).sub.o and (N).sub.n are nucleotides, (N)o and (N)n are optionally able to interact by hydrogen bond interaction; L is a linker which may be present or absent, but when present, is a nucleotide and/or a non-nucleotide linker, which may be a single-stranded and/or double-stranded region; Z3 is 2'-methylthiomethyl uridine; Z4 is 2'-methylthiomethyl cytidine; Z7 is pyridine-4-one; and_ represents a chemical linkage; and A, and G represent adenosine and guanosine nucleotides, respectively. 6. The nucleic acid molecules of any of claims 1-5, wherein said (N).sub.o and (N).sub.n are nucleotides and said o and n are integers greater than or equal to 3. 7. The nucleic acid molecules of any of claims 1-5, wherein said L is nucleotide linker. 8. The nucleic acid molecule of any of claims 1-5, wherein said nucleic acid cleaves a separate nucleic acid molecule. 9. The nucleic acid molecule of claim 8, wherein said separate nucleic acid molecule is RNA. 10. The nucleic acid molecule of claim 8, wherein said nucleic acid comprises between 12 and 100 bases complementary to said separate nucleic acid molecule. 11. The nucleic acid molecule of claim 8, wherein said nucleic acid comprises between 14 and 24 bases complementary to said separate nucleic acid molecule. 12. A cell including the nucleic acid molecule of any of claims 1-5. 13. The cell of claim 12, wherein said cell is a mammalian cell. 14. The cell of claim 13, wherein said cell is a human cell. 15. An expression vector comprising nucleic acid sequence encoding at least one of the nucleic acid molecule of any of claims 1-5, in a manner which allows expression of that nucleic acid molecule. 16. A cell including the expression vector of claim 15. 17. The cell of claim 16, wherein said cell is a mammalian cell. 18. The cell of claim 16, wherein said cell is a human cell. 19. A pharmaceutical composition comprising the nucleic acid molecule of any of claims 1-5. 20. The nucleic acid molecule of claims 1-5, wherein said nucleic acid is chemically synthesized. 21. The expression vector of claim 15, wherein said vector comprises: a) a transcription initiation region; b) a transcription termination region; c) a gene encoding at least one said nucleic acid molecule; and wherein said gene is operably linked to said initiation region and said termination region, in a manner which allows expression and/or delivery of said nucleic acid molecule. 22. The expression vector of claim 15, wherein said vector comprises: a) a transcription initiation region; b) a transcription termination region; c) an open reading frame; d) a gene encoding at least one said nucleic acid molecule, wherein said gene is operably linked to the 3'-end of said open reading frame; and wherein said gene is operably linked to said initiation region, said open reading frame and said termination region, in a manner which allows expression and/or delivery of said nucleic acid molecule. 23. The expression vector of claim 15, wherein said vector comprises: a) a transcription initiation region; b) a transcription termination region; c) an intron d) a gene encoding at least one said nucleic acid molecule; and wherein said gene is operably linked to said initiation region, said intron, and said termination region, in a manner which allows expression and/or delivery of said nucleic acid molecule. 24. The expression vector of claim 15, wherein said vector comprises: a) a transcription initiation region; b) a transcription termination region; c) an intron d) an open reading frame e) a gene encoding at least one said nucleic acid molecule, wherein said gene is operably linked to the 3'-end of said open reading frame; and wherein said gene is operably linked to said initiation region, said intron, said open reading frame, and said termination region, in a manner which allows expression and/or delivery of said nucleic acid molecule.

Details for Patent 6,548,657

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2017-06-09
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2017-06-09
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2017-06-09